<DOC>
	<DOCNO>NCT02329912</DOCNO>
	<brief_summary>Postoperative ileus ( POI ) frequent complication abdominal surgery lead nausea , vomit infectious complication . Bowel dysmotility last day necessitate parenteral nutrition result prolonged hospital stay high economic burden . Until evidence base therapy manifest POI miss valid surrogate marker demonstrate severity resolution POI . A novel tool examine gastrointestinal function SmartPill® . By measure pH value , temperature intraluminal pressure capsule able analyse gastric emptying , small bowel transit , large bowel transit peristaltic activity . Unfortunately use SmartPill® allow first three month abdominal surgery . Therefore trial need investigate behaviour SmartPill® passage human gastrointestinal tract immediately surgery . The primary endpoint - investigate safety SmartPill® patient abdominal surgery . The secondary endpoint : - SmartPill® able detect gastrointestinal transit peristaltic activity follow abdominal surgery compare patient underwent thoracic/vascular surgery . - possible correlate measure parameter ( delay gastrointestinal transit , lack peristalsis ) clinical sign POI ( nausea , vomit , prolonged duration first postoperative defecation ) . - detected peristaltic activity influence intravenous applicated prokinetic drug - detect peristaltic activity influence physiotherapy Using endpoint investigator hope demonstrate safety SmartPill® abdominal surgery , evaluate ability analyse severity length POI examine whether use prokinetic drug postoperative mobilization able influence peristaltic activity .</brief_summary>
	<brief_title>Postoperative Ileus : Duration Severity Assessment With SmartPill®</brief_title>
	<detailed_description>Postoperative ileus ( POI ) frequent complication abdominal surgery lead nausea , vomit infectious complication . Bowel dysmotility last day necessitate parenteral nutrition result prolonged hospital stay high economic burden . Until evidence base therapy manifest POI . Instead , quality exist clinical trial low moderate quality . The main reason lack valid surrogate marker define end POI : Some trial use first flatus first defecation marker purposeful peristalsis resolution POI , others use ability consume solid food auscultation bowel sound . However remain questionable whether parameter really able demonstrate severity end POI . Therefore POI research need reliable , patient investigator independent parameter able determine resolution POI improve quality future clinical trial . A novel tool examine gastrointestinal function SmartPill® . The capsule able measure pH value , temperature intraluminal pressure oral application , data send transmitter locate near patient . Using value , possible analyse gastric emptying , length small bowel , large bowel whole gut passage smooth muscle contractility/peristalsis whole gastrointestinal tract . Therefore SmartPill® would ideal , patient investigator independent tool investigate gastrointestinal function transit time visceral surgery . Unfortunately use SmartPill® allow first three month abdominal surgery . Therefore trial need investigate behaviour SmartPill® passage human gastrointestinal tract immediately surgery . The primary endpoint - investigate safety SmartPill® patient abdominal surgery . The secondary endpoint : - SmartPill® able detect gastrointestinal transit peristaltic activity follow abdominal surgery compare patient underwent thoracic/vascular surgery . - possible correlate measure parameter ( delay gastrointestinal transit , lack peristalsis ) clinical sign POI ( nausea , vomit , prolonged duration first postoperative defecation ) . - detected peristaltic activity influence intravenous applicated prokinetic drug - detect peristaltic activity influence physiotherapy Using endpoint investigator hope demonstrate safety SmartPill® abdominal surgery , evaluate ability analyse severity lenght POI examine whether use prokinetic drug postoperative mobilization able influence peristaltic activity .</detailed_description>
	<mesh_term>Ileus</mesh_term>
	<criteria>abdominal surgery thoracic/periphery vascular surgery estimate operation time &gt; 90 min &lt; 10 h Age &gt; 18 year write informed consent ASA score I III negative serum pregnancy test allergy device component device exist plan pregnancy emergency surgery NSAID ( non steroidal antiinflammatory drug ) induce enteropathy BMI &gt; 40 dysphagia medical history gastric bezoars medication proton pump inhibitor , H2blockers antacids necessity MRI first two week operation ASA score IV high gastroesophageal reflux ( `` Savary Miller '' III IV ) anastomosis esophagus jejunum fistula stenosis GI tract treat operation active Crohn´s disease Diverticulitis/severe diverticulosis , treat operation follow operation : kind organ transplantation , extend liver resection ( extend right left hemihepatectomy ) , low rectum resection without loop ileostoma , small bowel resection endtoend anastomosis , near total gastrectomy , transhiatal extend gastrectomy patient undergo abdominal surgery increase bleed propensity ( INR &gt; 2 , thrombocytes &lt; 50 G/l ... ) perioperative treatment ciclosporin , tacrolimus , sirolimus , everolimus , methotrexate , Decortin &gt; 15 mg/d , bevazicumab complete inspection adhesion , fistula etc . possible operation unexpected event operation ( major bleed transfusion 2 erythrocyte concentrate , hazardously anastomosis ) mention surgeon</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>postoperative ileus</keyword>
	<keyword>SmartPill</keyword>
	<keyword>gastrointestinal transit</keyword>
	<keyword>prokinetic drug</keyword>
</DOC>